Natixis Investment Managers International grew its position in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 13.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,667 shares of the medical equipment provider’s stock after purchasing an additional 308 shares during the period. Natixis Investment Managers International’s holdings in Boston Scientific were worth $183,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC lifted its stake in Boston Scientific by 542.1% during the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 309 shares in the last quarter. First Foundation Advisors acquired a new stake in shares of Boston Scientific in the first quarter valued at $25,000. RiverPark Advisors LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at $30,000. Northwest Investment Counselors LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at $31,000. Finally, Sachetta LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $32,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.
Boston Scientific Stock Performance
Shares of BSX traded down $3.50 during mid-day trading on Thursday, hitting $74.26. 10,900,652 shares of the company’s stock were exchanged, compared to its average volume of 6,285,901. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $79.43. The firm has a market capitalization of $108.95 billion, a P/E ratio of 62.40, a P/E/G ratio of 2.70 and a beta of 0.78. The business’s 50 day moving average is $76.48 and its two-hundred day moving average is $70.20. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47.
Wall Street Analysts Forecast Growth
BSX has been the topic of several analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price objective on shares of Boston Scientific in a research note on Thursday. Deutsche Bank Aktiengesellschaft increased their price objective on Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research note on Thursday. Citigroup increased their target price on Boston Scientific from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. BTIG Research increased their target price on Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a report on Monday, July 15th. Finally, Barclays increased their target price on Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $84.76.
View Our Latest Stock Analysis on BSX
Insider Transactions at Boston Scientific
In other news, Director Edward J. Ludwig sold 9,818 shares of the stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares in the company, valued at $3,032,300.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Charles J. Dockendorff sold 3,946 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total value of $286,874.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 9,818 shares of the firm’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,259 shares of company stock worth $5,344,014. Company insiders own 0.50% of the company’s stock.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
See Also
- Five stocks we like better than Boston Scientific
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- What is the NASDAQ Stock Exchange?
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.